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There are limited data on the differences in the impact 
of psoriasis between various countries with respect 
to quality of life (QoL). The aim of this study was to 
explore the psychosocial health of patients with pso-
riasis in different European countries. A total of 682 
patients were recruited in 13 European countries. All 
patients completed a questionnaire regarding socio-
demographic information, negative life events, suici-
dal ideation and satisfaction with their dermatologist. 
Depression and anxiety were assessed with the Hos-
pital Anxiety and Depression Scale (HADS), and QoL 
with the Dermatology Life Quality Index (DLQI) and 
EuroQoL (EQ-5D). The lowest anxiety and depression 
scoring was noted in patients from Denmark, the lo-
west level of impairment in QoL in subjects from Spain, 
and the highest level of impairment in QoL in patients 
from Italy. The most relevant parameters influencing 
patients’ well-being were severity of pruritus and sa-
tisfaction with their dermatologist. The level of anxiety 
and depression symptoms correlated significantly with 
suicidal ideation. 
Key words: psoriasis; quality of life; depression; anxiety; self-
esteem.
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Psoriasis is a common chronic inflammatory skin disorder with a substantial emotional impact on 
patients. Prevalence studies have shown uniformly high 
rates of psychopathology among people with psoriasis 
(1–4). For instance, anxiety symptoms were found much 
more commonly in patients with psoriasis compared with 
controls, with an adjusted odds ratio (OR) of 2.91 (95% 
confidence interval (95% CI) 2.01–4.21) for anxiety dis-
orders in subjects with psoriasis (4). People with psoriasis 
were also more likely to be clinically depressed (1). Of 
note, psychological factors, such as stress, anxiety and 
depressed mood, may influence the course of the disease 
and, along with the impact of psoriatic symptoms, impair 
patients’ quality of life (QoL). Importantly, the impact 
of psoriasis on health-related QoL (HRQoL) seems to 
be as great as that of other major medical conditions, 
such as cancer, heart failure, diabetes and depression (3). 
Moreover, there was a significant association between 
having psoriasis and having suicidal thoughts: 67.6% of 
subjects with psoriasis reported suicidal ideation because 
of their skin problem (4). Depression in psoriasis might 
also be linked with higher cardiovascular morbidity and 
mortality, as it may play a role in promoting subclinical 
atherosclerosis beyond traditional cardiovascular risk 
factors. It was shown that depression might be associated 
with increased vascular inflammation and formation of 
coronary plaques (5, 6). Therefore, it could be recom-
mended that patients with psoriasis should be systema-
tically screened to identify clinically important levels 
of depression and anxiety that may be missed while 
assessing HRQoL alone (7).
It is not known whether depression level and other 
psychopathological symptoms in psoriasis correlate with 
disease severity, as current data are contradictory. Some 
authors have suggested that social stigmatization, high 
stress levels, physical limitations, depression, employ-
ment problems and other psychosocial co-morbidities 
experienced by patients with psoriasis are not always 
proportional to, or predicted by, other measurements of 
disease severity, such as body surface area involvement 
or plaque severity (2). However, other researchers report 
that the severity of psoriasis has a significant impact on 
the wellbeing of affected individuals, as the burden of 
overall medical comorbidities increases with disease 
severity in the psoriatic population, and severe psoriasis 
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increases overall mortality, while mild psoriasis does not 
(8, 9). Therefore, although there may be discordance 
between severity of skin lesions and distress, severity of 
psoriasis may have some effect on rates of depression 
and suicidality (8).
The psychosocial health of psoriatic patients may be 
influenced not only by the disease itself, but also by 
other factors, such as patients’ economic status, occu-
pation and family support. Also, wider factors, such as 
the healthcare system organization, access to different 
therapeutic options, or even climate may play a role 
(10, 11). However, despite the psychological aspects 
of psoriasis having been widely reported, there is little 
comparative information from different countries (12, 
13). It is probable that patients with psoriasis from dif-
ferent regions may perceive their disease differently. In 
the present study we performed detailed analysis of data 
to identify differences among psoriatic patients from 
various countries, especially regarding determinants of 
psychosocial health deterioration, including HRQoL, 
anxiety and depression. 
MATERIALS AND METHODS
This study focused on the psoriatic patients participating in the 
project “The psychological burden of skin diseases: a cross-sec-
tional multicenter study among dermatological outpatients in 13 
European countries” run by the European Society of Dermatology 
and Psychiatry (ESDaP). In this observational, cross-sectional 
multicentre study, patients were recruited from dermatological 
outpatient clinics in 13 European countries from November 2011 
to February 2013. At each study centre consecutive adult out-
patients were invited to participate in the study on one or more 
random days, until 250 participants per centre were reached. The 
study protocol was approved by the Regional Committee for 
Medical Research Ethics in Norway (REK 2011/1087). Local 
ethics approval was also obtained in all participating countries. 
The study was conducted in accordance with the principles of the 
Declaration of Helsinki. 
All patients participating in the study met the following inclusion 
criteria: age ≥ 18 years; able to read and write in the local language; 
no severe psychosis. Subjects provided signed informed consent 
and were examined for dermatological and other physical condi-
tions. Further details of the study have been published elsewhere 
(4). Out of a total of 3,635 dermatological patients recruited, 682 
(18.8%) had psoriasis and were included in the current study for 
a separate analysis. The group had a mean age of 47.0 ± 15.6 years 
and 54.2% were male. All patients completed a questionnaire re-
garding socio-demographic information, negative life events and 
suicidal ideation. Whenever itch was reported, its severity was 
assessed using a visual analogue scale (VAS) and subsequently 
categorized as mild (> 0 and < 3 points), moderate (≥ 3 and < 7 
points), severe (≥ 7 and < 9 points) and very severe pruritus (≥ 9 
points) (14, 15). Anxiety and depression were assessed with the 
Hospital Anxiety and Depression Scale (HADS), on which a hig-
her score means a higher level of anxiety or depression (16), and 
HRQoL was assessed with the Dermatology Life Quality Index 
(DLQI) (a skin-specific QoL measure) (17) and the EuroQoL (EQ-
5D, a generic QoL measure) (18). All instruments were validated 
in the native languages of participating countries. According to 
HADS anxiety/depression were considered as unlikely, possible 
and probable, if a patient received < 7 points, 8–10 points and > 10 
points in each subscale, respectively. The DLQI is a 10-item QoL 
scale assessing “symptoms and feelings”, impairment of “daily 
activities”, “leisure”, “work and school” and “personal relations-
hips”, as well as “treatment” burden with respect to skin diseases; 
a higher DLQI score signifies higher impairment of HRQoL (17). 
Using the EQ-5D, the respondent was asked to indicate his/her 
general health status indicating the most appropriate statement in 
each of the 5 predefined dimensions, and answers were converted 
into scores, with a higher score referring to a higher disease burden. 
In addition, each participant recorded their self-rated health status 
with the EQ-5D VAS, where the endpoints were “Best imaginable 
health state” (0 points) and “Worst imaginable health state” (100 
points) (18). Patients were also asked about their satisfaction with 
their dermatologist (from 0 to 10) and whether they were having or 
had had suicidal thoughts in the past (yes/no). If they confirmed the 
presence of suicidal thoughts they were also asked whether their 
suicidal thoughts were because of their skin condition (yes/no). 
Finally, skin disease severity was assessed by the dermatologist 
using a scale of “mild, “moderate” or “severe”. 
The results were analysed using Statistica® and Microsoft Ex-
cel® software. Frequencies (percentage values) were calculated 
for qualitative parameters, while means and standard deviations 
were calculated for normally distributed quantitative variables. 
The χ2 test, Student’s t-test, multiple regression analysis, analysis 
of variance (ANOVA) and Pearson’s correlation test were used, 
where appropriate. Statistical significance level was set at 0.05.
RESULTS
Differences between psoriatic patients from various 
European countries
A total of 151 psoriatic patients (22.1%) had HADS-A 
scoring ≥ 11 points (indicating clinically relevant anx-
iety) and 91 patients (13.3%) recorded marked depres-
sive symptoms (≥ 11 points). Significant differences 
regarding self-assessed overall health status, HRQoL, 
anxiety and depression were observed among psoriatic 
patients from various European countries (Table I). The 
lowest anxiety and depression values were scored by 
patients from Denmark (HADS-anxiety: 5.0 ± 4.4 points, 
HADS-depression: 3.2 ± 3.2 points); and the best HRQoL 
was observed in subjects from the Netherlands (overall 
health status: 77.9 ± 14.4%; DLQI: 6.5 ± 5.2 points) and 
Spain (overall health status: 74.9 ± 16.8%; DLQI: 3.7 ± 4.9 
points), while patients from Italy were the most impaired 
(HADS-anxiety: 10.6 ± 3.9 points, HADS-depression: 
9.6 ± 4.4 points, overall health status: 55.6 ± 22.2%, 
DLQI: 14.3 ± 6.6) (Fig. 1). Detailed data on anxiety and 
depression in particular countries are shown in Table SI1.
Analysis of psychosocial health status with respect to 
demographic data and disease severity
Analysis of demographic and socio-economic factors 
revealed significant correlation between age and gene-
ral health status assessed with EQ-5D, indicating that 
higher age was associated with poorer general quality 
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2760
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of life (EQ-questionnaire r = 0.15, p < 0.001 and EQ-
VAS r = –0.12, p = 0.002), and between age and HRQoL 
impairment measured with DLQI (similarly, higher 
age was linked with more decreased HRQoL, r = –0.11, 
p = 0.005). Also, there was significant correlation, albeit 
weak, between patients’ age and satisfaction with their 
dermatologist, indicating that older people are more sa-
tisfied with their treating physicians (r = 0.12, p = 0.003) 
(Table II). 
Statistically significant differences between males and 
females were demonstrated in all analysed aspects, ex-
cept satisfaction with their dermatologists. Females pre-
sented lower overall health status, more intense anxiety 
and depression symptoms, greater HRQoL impairment 
and more intense itch compared with males (Table II).
The degree of satisfaction with a dermatologist was 
inversely proportional to the level of education. There 
was a low level of anxiety in patients with lower edu-
cational attainment, and a high level of anxiety in those 
with higher educational attainment (Table II).
There were no statistically significant relationships 
between level of education and severity of pruri-
Table I. EuroQoL (EQ-5D), Hospital Anxiety and Depression Scale (HADS) and Dermatology Life Quality Index (DLQI) scoring for psoriatic 
patients from various European countries 
Country (% of all patients 
from each country)
General health status
Mean ± SD [95% CI]
Self-rated health status – 
EQ-5D
Mean ± SD [95% CI]
HADS – Anxiety
Mean ± SD [95% CI]
HADS – Depression
Mean ± SD [95% CI]
DLQI
Mean ± SD [95% CI]
Belgium (n = 43, 17.4%) 6.7 ± 1.4 [6.2–7.1] 70.2 ± 14.8 [65.3–75.0] 9.5 ± 4.7 [7.9–10.9] 5.6 ± 4.1 [4.1–6.8] 5.7 ± 5.0 [4.1–7.3]
Denmark (n = 46, 16.1%) 6.9 ± 1.6 [6.4–7.4] 70.3 ± 17.6 [64.7–75.8] 5.0 ± 4.4 [3.7–6.4] 3.2 ± 3.2 [2.2–4.2] 5.2 ± 5.8 [3.4–7.1]
France (n = 17, 13.2%) 6.9 ± 1.3 [6.2–7.6] 69.1 ± 16.5 [60.6–77.6] 7.8 ± 3.2 [6.1–9.4] 5.0 ± 3.3 [3.3–6.7] 5.7 ± 5.7 [2.5–8.8]
Germany (n = 29, 9.9%) 7.4 ± 1.5 [6.9–8.0] 62.1 ± 22.4 [53.6–70.6] 8.6 ± 5.4 [5.6–9.1] 6.6 ± 5.1 [4.6–8.5] 10.4 ± 8.3 [7.3–13.6]
Hungary (n = 40, 9.8%) 6.4 ± 1.8 [5.8–7.1] 72.5 ± 18.8 [64.8–80.3] 5.1 ± 4.0 [3.8–6.4] 4.8 ± 4.1 [3.4–6.1] 6.1 ± 7.9 [3.5–8.6]
Italy (n = 83, 16.4%) 8.0 ± 1.8 [7.6–8.4] 55.6 ± 22.2 [50.8–60.5] 10.6 ± 3.9 [9.7–11.4] 9.6 ± 4.4 [8.7–10.6] 14.3 ± 6.6 [12.8–15.7]
Netherlands (n = 23, 11.5%) 6.4 ± 1.4 [5.8–7.0] 77.9 ± 14.4 [70.3–85.6] 5.4 ± 4.1 [3.6–7.2] 4.6 ± 3.9 [2.9–6.2] 6.5 ± 5.2 [4.3–8.7]
Norway (n = 138, 24.5%) 7.4 ± 1.8 [7.1–7.7] 65.9 ± 19.7 [62.5–69.4] 6.6 ± 4.5 [5.8–7.4] 4.4 ± 4.2 [3.6–5.1] 9.2 ± 7.2 [7.9–10.4]
Poland (n = 61, 22.4%) 7.7 ± 1.8 [7.2–8.1] 58.0 ± 20.2 [52.8–63.1] 7.6 ± 4.8 [6.3–8.7] 6.1 ± 3.9 [5.1–7.1] 13.3 ± 8.1 [11.2–15.4]
Russia (n = 73, 27.2%) 7.2 ± 1.7 [6.8–7.6] 63.9 ± 19.9 [59.2–68.5] 5.8 ± 4.0 [4.9–6.8] 5.2 ± 3.4 [4.4–6.0] 11.3 ± 7.7 [9.5–13.1]
Spain (n = 52, 20.1%) 6.1 ± 1.4 [5.7–6.5] 74.9 ± 16.8 [70.2–79.6] 6.2 ± 3.9 [5.0–7.2] 3.8 ± 3.2 [2.9–4.7] 3.7 ± 4.9 [2.3–5.1]
Turkey (n = 27, 10%) 7.4 ± 1.9 [6.6–8.2] 65.2 ± 18.1 [58.0–72.3] 6.4 ± 4.0 [4.8–8.0] 5.7 ± 3.9 [4.2–7.3] 11.1 ± 6.9 [8.4–13.9]
UK (n = 50, 18.3%) 6.8 ± 2.0 [6.3–7.4] 70.0 ± 17.0 [65.1–74.9] 7.1 ± 4.1 [6.0–8.3] 4.8 ± 4.0 [3.7–5.9] 6.8 ± 7.2  [4.8–8.9
SD: standard deviation; 95% CI: 95% confidence interval.
Fig. 1. Values obtained in different countries. 
(A) Own health status assessed with EuroQoL (EQ-
5D) (red: feeling of poor health, orange: feeling 
of moderate health; yellow: feeling of quite good 
health, green: feeling of good health). (B) Anxiety 
level assessed with Hospital Anxiety and Depression 
Scale (HADS-A) anxiety subscale (green: anxiety 
unlikely, orange: suspected anxiety, red: clinically 
relevant anxiety). (C) Depressive symptoms 
assessed with the HADS-D depression subscale 
(green: depression unlikely, orange: suspected 
depression, red: clinically relevant depression). (D) 
Quality of life (QoL) assessed with Dermatology Life 
Quality Index (DLQI) (grass green: normal QoL, 
green: slightly impaired QoL, yellow: moderately 
impaired QoL, orange: severely impaired QoL, 
red: extremely impaired QoL).
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tus (p = 0.23), overall health status 
(p = 0.19, p = 0.21), severity of de-
pressive symptoms (p = 0.4) and 
HRQoL (p = 0.12). Marital status 
was significantly linked with itch 
intensity, general health status (EQ-
5D questionnaire) and severity of 
anxiety and depressive symptoms. 
Divorced people reported more in-
tense itch, higher overall health status 
impairment, higher anxiety level and 
more severe depressive symptoms. 
There were no statistically significant 
differences between marital status 
regarding satisfaction with a derma-
tologist (p = 0.13), self-rated health 
status (EQ-5D VAS) (p = 0.13) and 
QoL (p = 0.22) (Table II).
Patients with the lowest socio-
economic status (status self-assessed 
by the respondent as low, middle, 
or high) demonstrated the highest 
overall health status impairment, had 
more severe anxiety and depressive 
symptoms and the highest HRQoL 
impairment (Table II).
Disease severity was weakly rela-
ted to patient’s psychosocial health 
status, documenting that higher 
disease severity was linked with 
poorer well-being. The closest re-
lationship was with DLQI score 
(r = 0.21, p < 0.001), followed by 
EQ-5D score (r = 0.18, p < 0.001), 
EQ-5D VAS (r = –0.17, p < 0.001), 
depression (r = 0.14, p < 0.001), and 
anxiety (r = 0.1, p < 0.001). A detai-
led multiple regression analysis on 
the studied variables influencing the 
patient well-being is presented in 
Table SII1. 
Suicidal thoughts in psoriatic 
population
A total of 115 patients out of 668 
(17.2%) reported present or past 
suicidal ideations; out of these pa-
tients, 77 (11.5%) stated such idea-
tions to be related to their psoriasis. 
These patients were characterized 
by significantly higher severity of 
pruritus, lower overall health status, 
more severe anxiety and depressive 
symptoms, and lower HRQoL com-
pared with patients without suicidal Ta
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ideation (Table III). The highest prevalence of suicidal 
thoughts was found in Turkey (44.4%), the lowest in 
France (5.9%) and the second lowest in Denmark (9.1%) 
(p = 0.02). 
Multiple regression analysis revealed that the pre-
sence of suicidal thoughts was independently related to 
patients’ age (β = –0.1, p < 0.05), socio-economic level 
(β = –0.09, < 0.05), stressful life events during the last 6 
months (β = –0.18, p < 0.001), general health status ac-
cording to EQ-5D questionnaire (β = 0.12, p = 0.04), and 
anxiety level (β = 0.25, p < 0.001), while suicidal ideation 
related to skin condition were significantly dependent 
only on stressful life events during the last 6 months 
(β = –0.1, p < 0.05), and anxiety level (β = 0.24, p < 0.001).
Itching in psoriatic patients
A total of 474 psoriatic patients (69.5%) reported itching, 
of whom 74.7% reported the presence of chronic itch, i.e. 
lasting longer than 6 weeks. In some countries the preva-
lence of itch was extremely high (Italy 91.6%, Germany 
82.8%, the Netherlands 82.6%) in comparison with some 
other countries (France 35.3%, UK 52.0%) (p < 0.001). 
Significant differences were also observed regarding itch 
intensity, with the highest scores reported among patients 
from Italy (mean VAS 6.6 ± 1.9 points), UK (mean VAS 
5.8 ± 2.3) and Germany (mean VAS 5.7 ± 3.2), and the 
lowest scores by patients living in Russia (mean VAS 
2.5 ± 3.2), Hungary (mean VAS 3.5 ± 3.3) and Spain (mean 
VAS 3.5 ± 3.3) (p < 0.001). Detailed data on itch severity 
scoring are demonstrated in Table SIII1.
Patients with chronic itch had more severe pruritus 
than those with acute itch (6.0 ± 2.5 points vs. 5.3 ± 2.4, 
p < 0.01). They were also more depressed (Table IV). 
Patients with itch had lower overall health status and 
HRQoL as well as significantly more severe anxiety and 
depressive symptoms compared with patients without 
itch. There was a statistically significant correlation 
between the severity of itch and satisfaction with der-
matologist, overall health status, severity of anxiety and 
depression symptoms, and HRQoL (Table IV).
DISCUSSION
Psoriasis is a common chronic skin condition that can 
markedly impair patients’ HRQoL (19–21). Many people 
with psoriasis report decreased self-esteem and problems 
in establishing relationships with other people (22). 
However, in our current study using a validated set of 
questionnaires we have demonstrated significant varia-
tions among different European countries of psychosocial 
health status of patients with psoriasis. It is possible 
that cultural differences, different access to possible 
treatments, differences in the organization of healthcare 
systems, and differences in climate may influence the 
impact of psoriasis on patient’s well-being. Differences 
regarding well-being do not correlate with latitude, 
Table III. Relationships between suicidal ideation and psychosocial well-being of psoriatic patients
Presence of suicidal ideation
(n = 115)
Suicidal ideation related to skin condition
(n = 77)
Yes 
Mean ± SD [95% CI]
No 
Mean ± SD [95% CI] p-value
Yes 
Mean ± SD [95% CI]
No 
Mean ± SD [95% CI] p-value
Itch intensity 5.8 ± 3.1 [5.2–6.4] 4.4 ± 3.0 [4.1–4.7] < 0.001 6.0 ± 2.9 [5.3–6.7] 4.5 ± 3.1 [4.2–4.7] < 0.001
Satisfaction with your dermatologist 7.0 ± 3.0 [6.4–7.5] 7.8 ± 2.5 [7.6–8.1] < 0.01 7.2 ± 2.9 [6.5–7.8] 7.8 ± 2.6 [7.5–8.0] 0.07
General health status: EQ-5D questionnaire 8.4 ± 1.8 [8.1–8.7] 6.9 ± 1.7 [6.8–7.0] < 0.001 8.7 ± 1.8 [8.3–9.1] 7.0 ± 1.7 [6.8–7.1] < 0.001
Self-rated health status: EQ-5D (VAS) 55.8 ± 21.6 [51.7–59.8] 67.7 ± 19.0 [66.1–69.4] < 0.001 53.3 ± 21.6 [48.3–58.3] 67.3 ± 19.1 [65.7–68.9] < 0.001
Anxiety level: HADS 11.2 ± 4.9 [10.2–12.0] 6.3 ± 3.9 [5.9–6.5] < 0.001 11.4 ± 4.7 [10.3–12.4] 6.6 ± 4.2 [6.2–6.9] < 0.001
Depression level: HADS 8.9 ± 4.7 [7.9–9.7] 4.7 ± 3.8 [4.3–5.0] < 0.001 9.3 ± 4.6 [8.2–10.3] 4.9 ± 4.0 [4.6–5.2] < 0.001
QoL: DLQI 13.7 ± 8.4 [12.2–15.3] 8.2 ± 7.1 [7.6–8.8] < 0.001 15.6 ± 8.1 [13.8–17.5] 8.3 ± 7.1 [7.7–8.9] < 0.001
SD: standard deviation; 95% CI: 95% confidence interval; QoL: quality of life; VAS: visual analogue scale; EQ-5D: EuroQoL; HADS: Hospital Anxiety and Depression 
Scale; DLQI: Dermatology Life Quality Index.
Table IV. Relationships between itch and psychosocial parameters in psoriatic patients
Presence of itch Chronic itch (>6 weeks)a Itch intensity
Yes
(n = 474) 
Mean ± SD [95% CI]
No
(n = 208) 
Mean ± SD [95% CI] p-value
Yes
(n = 313) 
Mean ± SD [95% CI]
No
(n = 106) 
Mean ± SD [95% CI] p-value r p-value
Satisfaction with your 
  dermatologist
7.4 ± 2.7 [7.1–7.6] 8.4 ± 2.2 [8.1–8.8 < 0.001 7.2 ± 2.6 [6.7–7.7] 7.3 ± 2.8 [7.0–7.7] 0.67 –0.21 < 0.001
General health status: 
  EQ-5D questionnaire 
7.5 ± 1.8 [7.3–7.6 6.4 ± 1.5 [6.2–6.7 < 0.001 7.3 ± 1.7 [7.0–7.7] 7.6 ± 1.9 [7.4–7.8] 0.20 0.37 < 0.001
Self-rated health status: 
  EQ-5D (VAS) 
62.9 ± 20.5 [61.0–64.8 72.4 ± 16.6 [70.0–74.8 < 0.001 62.4 ± 19.6 [58.5–66.3] 62.2 ± 21.2 9.8–64.6] 0.93 –0.30 < 0.001
Anxiety level: HADS 7.7 ± 4.7 [7.3–8.1 5.7 ± 3.8 [6.1–6.2 < 0.001 8.2 ± 4.6 [7.3–9.1] 7.6 ± 4.7 [7.0–8.1] 0.26 0.35 < 0.001
Depression level: HADS 6.2 ± 4.5 [5.8–6.6 3.7 ± 3.0 [3.2–4.1 < 0.001 7.4 ± 4.8 [6.4–8.3] 6.0 ± 4.3 [5.5–6.5] < 0.001 0.34 < 0.001
QoL: DLQI 10.9 ± 7.6 [10.2–11.6 4.9 ± 5.9 [4.1–5.8 < 0.001 11.2 ± 7.2 [9.8–2.6] 11.6 ± 7.7 [10.7–12.4] 0.66 0.47 < 0.001
aIn 55 patients the duration of itch was not provided.
SD: standard deviation; 95% CI: 95% confidence interval; QoL: quality of life; VAS: visual analogue scale; EQ-5D: EuroQoL; HADS: Hospital Anxiety and Depression 
Scale; DLQI: Dermatology Life Quality Index.
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ambient temperature or sun exposure, or with national 
prosperity. The percentage of patients with psoriasis 
recruited in each centre was highest in Russia, Norway 
and Poland, and lowest in Turkey, Germany and Hungary. 
Differences in the patient number included in particular 
centres may limit the validity of results achieved. In this 
respect, a further limitation of this study is the lack of 
data on patients’ nationality, in respect of their duration of 
stay in the country in which they had been recruited into 
the study. Another limitation of the study is that patients 
were recruited on random days, which might not ensure 
proper random sampling, as some types of patients may 
be seen on certain days of the week. 
Analysis of other demographic data revealed statisti-
cally significant differences between males and females 
in all aspects except for satisfaction with the dermato-
logist. Females, as also reported by other authors (1, 
23), presented lower overall health status, more intense 
anxiety and depression symptoms, greater HRQoL im-
pairment and more intense itch compared with males. In 
addition, links were demonstrated between satisfaction 
with a dermatologist and level of education, between ma-
rital status and itch intensity, general health status (EQ-
5D questionnaire), anxiety and depressive symptoms 
severity, between socio-economic status and severity of 
itch, overall health status, severity of anxiety and depres-
sive symptoms and HRQoL impairment (see Table II). 
One of the most important aspects of psoriasis is 
concomitant pruritus. Approximately 72–80% of pso-
riatic patients may experience pruritus (22, 24) and this 
symptom may be one of the main factors influencing 
their HRQoL (25). The present study confirmed that 
pruritus is very frequent in psoriasis, and that its seve-
rity is one of the main parameters affecting psoriatic 
patients’ well-being throughout different European 
countries. As shown, pruritus is considered by patients 
to be the most bothersome symptom of psoriasis, even 
though the severity of itch appears to be lower than in 
other pruritic skin conditions (26). Patients with pruritus 
show more reduced HRQoL compared with those without 
pruritus, and pruritus intensity correlates with the degree 
of HRQoL impairment (26). Pruritus may alter sleep 
quality, which may further contribute to the alteration 
of psoriatic patients’ well-being. Psoriatic subjects with 
pruritus also demonstrate more depressive symptoms 
(27). This finding may, at least in part, explain the link 
between pruritus and suicidal ideation, as we found a 
clear link between the intensity of anxiety and depres-
sion symptoms in psoriatic individuals and the presence 
of suicidal ideations. 
This study has several limitations. The way in which 
patients were recruited and the type of dermatology clini-
cal service may have differed between centres. Although 
the total number of general dermatology patients recrui-
ted at each centre was similar, the number of psoriatic 
patients depended on the sequential inclusion of psoriatic 
patients within the larger cohort, leading to differences 
in numbers of psoriatic patients recruited from each 
centre. Depending on the local system of referral to the 
clinic, the clinical severity of the psoriasis patients may 
have differed between centres. Some of the differences 
in scores between countries may have been caused by 
cultural differences in answering the questionnaires. 
Although validated translations of the measures were 
used in different countries, giving assurance that the 
meaning of the questions was as close as possible in the 
different languages, it cannot necessarily be assumed that 
the scores from the measures can be directly compared 
between different countries (28), even though this as-
sumption is made in the interpretation of, for example, 
multinational drug trials (29). This is a difficulty across 
all patient-reported outcome measurements in medicine 
and is not confined to dermatology. Furthermore, disease 
severity was assessed using only 3 severity categories 
(mild, moderate, severe). The Psoriasis Area and Seve-
rity Index (PASI) would probably be more appropriate 
as it gives more objective data on psoriasis severity and 
extent, thus not using PASI should be considered as a 
further limitation. The same refers to measurement of 
pruritus intensity, as the VAS is assessing only symptom 
severity, but does not take into account, for example, 
pruritus extent or number and durations of itch episodes. 
Thus, performing only one method of assessment of pru-
ritus severity limits the results for itch. According to the 
guidelines published by the International Forum for the 
Study of Itch (IFSI) (8) VAS is one of the most widely 
used pruritus measures and is recommended for use in all 
clinical trials on itch. Of course, this instrument, as any 
other, has some limitations, which have been mentioned 
in the discussion. 
Future studies focusing on the influence of pruritus on 
patient well-being should consider other measurement 
tools, such as itch questionnaires (30). However, despite 
the large number of questionnaires used in our study, in 
order to keep the study as feasible as possible we decided 
to include only VAS as a measure of pruritus intensity. 
In conclusion, significant variations were observed 
among different European countries regarding the 
psychosocial health status of patients with psoriasis. 
Patient selection biases may have partly influenced the 
results of the present study, and these findings need to 
be confirmed in future studies; however, this study in-
dicates that results from one country should not simply 
be transferred to patients living in other countries, as 
perception of psoriasis and coping with the disease may 
take place in a completely different ways. The study 
clearly indicates that psoriasis is significantly linked 
with depression, anxiety and impairment of QoL. It is 
essential to include measures of psychosocial morbidity 
when assessing psoriasis severity and treatment efficacy, 
because of the substantial role that psychosocial burden 
plays in patient perception of disease severity, QoL and 
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disease course (2). Such knowledge also requires the 
prompt implementation of active interventions to detect 
and treat psychological disturbances early, in order to 
improve QoL of patients with psoriasis. 
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